

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re Application of* )  
 )  
 Michael L. VAZQUEZ *et al.* ) Group Art Unit: TBA  
 )  
 Serial No. TBA ) Examiner: TBA  
 Divisional of U.S. Application )  
 Serial No. 10/199,481 ) Atty. Docket 101765.00032 (2705/17)  
 )  
 Filed: March 30, 2004 )

For: α- AND β-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


In accordance with 37 C.F.R. §§ 1.97 and 1.98 *et seq.*, enclosed is Form PTO 1449 listing documents for consideration and entry by the Examiner in the above-captioned patent application. With the exception of related U.S. Patent Nos. 6,455,581 and 6,060,476, all cited art was previously disclosed in parent Application Serial No. 10/199,481, filed July 22, 2002, which is relied on for an earlier effective filing date under 35 U.S.C. § 120. Copies of the previously-submitted documents are not being submitted herewith, in accordance with 37 C.F.R. § 1.98(d)(1). Also, copies of the above-cited related U.S. patents are not being submitted herewith, in accordance with the Official Gazette Notice dated August 5, 2003, waiving the requirement under 37 C.F.R. § 1.98(a)(2)(i) for submitting copies of cited U.S. patents in patent applications filed after June 30, 2003.

No fee is believed to be due for this submission. However, should a fee be required, the Commissioner is hereby authorized to debit our Deposit Account No. 19-0733, as necessary.

Entry and consideration of the cited information is respectfully requested together with a return of the PTO Form 1449 initialed by the Examiner indicating the same.

Respectfully submitted,

By:

  
Joseph M. Skerpon  
Registration No. 29,864

Date: March 30, 2004

BANNER & WITCOFF, LTD.  
1001 G Street, N.W., Suite 1100  
Washington, D.C. 20001-4597  
(202) 824-3000

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

**Complete if Known**

Application Number	TBA
Filing Date	March 30, 2004
First Named Inventor	VAZQUEZ et al.
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 101765.00032 (2705/17)

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
A	US-6,455,581		9/2002	Vazquez et al.	
B	US- 6,060,476		5/2000	Vazquez et al.	
AA	US-4,450,164		5/1984	Bristol et al.	
AB	US- 4,477,441		10/1984	Boger et al.	
AC	US- 4,514,391		4/1985	Gordon et al.	
AD	US- 4,548,926		10/1985	Matsueda et al.	
AE	US- 4,599,198		7/1986	Hoover	
AF	US- 4,616,088		10/1986	Ryono et al.	
AG	US- 4,668,769		5/1987	Hoover	
AH	US- 4,668,770		5/1987	Boger et al.	
AI	US- 4,757,060		7/1988	Natarajan et al.	
AJ	US- 4,880,938		11/1989	Freidinger	
AK	US- SIR H725		1/1990	Gordon	
AL	US- 4,963,530		10/1990	Hemmi et al.	
AM	US- 4,977,277		12/1990	Rosenberg et al.	
AN	US- 5,585,397		12/1996	Tung et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
AO		AU 79823	04/1988			
AP		EP 0 264 795	04/1988			
AQ		EP 104 041	03/1984			
AR		EP 114 993	08/1984			
AS		EP 172 347	02/1986			
AT		EP 223 437	05/1987			
AU		EP 0 264 795	04/1988			
AV		EP 337 714	10/1989			
AW		EP 342 541	10/1989			
AX		EP 346 847	12/1989			
AY		EP 356 223	02/1990			
AZ		EP 389 898 A2	10/1990			

Examiner Signature

Date Considered

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	TBA		
		Filing Date	March 30, 2004		
		First Named Inventor	VAZQUEZ et al.		
		Group Art Unit	TBA		
		Examiner Name	TBA		
Sheet	2	of	2	Attorney Docket Number	101765.00032 (2705/17)

<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
BA		EP 393 445	10/1990			
BB		EP 393 457	10/1990			
BC		EP 402646	12/1990			
BD		EP 468641	01/1992			
BE		GB 2 184 730	07/1987			
BF		GB 2 200 115	07/1988			
BG		GB 2 209 752	05/1989			
BH		WO 84/03044	08/1984			
BI		WO 92/08599	05/1992			

<b>OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS</b>							
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>2</sup>
	BJ	Erickson et al., "Design Activity, and 2.8Å Crystal Structure of a C2 Symmetric Inhibitor Complexed to HIV-1 Protease," <i>Science</i> , 249, 527 (1990).					
	BK	Martin, <i>Drugs f the Future</i> , 16(3), 210-212 (1991).					
	BL	McQuade et al., <i>Science</i> , 247, 454-456 (1990).					
	BM	Meek et al., <i>Letter to Nature</i> , 343, 90-92 (1990).					
	BN	Pearl et al., "Sequence Specificity of Retroviral Proteases," <i>Nature</i> , 328 (1987).					
	BO	Rich et al. "Peptide Inhibitors of Proteases, 511-520 (1983).					
	BP	Roberts et al., "Rational Design of Peptide-based Proteinase Inhibitors," <i>Science</i> , 248, 358 (1990).					
	BQ	Rosenberg et al., <i>J. Med. Chem.</i> , 30, 1224-1228 (1987).					

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.